Spots Global Cancer Trial Database for myelosuppression
Every month we try and update this database with for myelosuppression cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL) | NCT03098589 | Lymphoma | Revlimid | 18 Years - | Celgene | |
| Efficacy and Safety Phase IIa Study of Myelo001 in Chemotherapy-Induced Neutropenia | NCT02692742 | Chemotherapy-In... Myelosuppressio... Breast Cancer | Myelo001 Placebo | 18 Years - | Myelo Therapeutics GmbH | |
| Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan | NCT05874401 | Extensive-stage... | Trilaciclib Placebo Topotecan | 18 Years - | G1 Therapeutics, Inc. | |
| Complementary Treatment of PG2 to Improve Clinical Benefit Response and Quality of Life in Fatigue | NCT00518869 | Quality of Life Fatigue Complementary | PG2 | 17 Years - 75 Years | PhytoHealth Corporation | |
| Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan | NCT05874401 | Extensive-stage... | Trilaciclib Placebo Topotecan | 18 Years - | G1 Therapeutics, Inc. | |
| Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer | NCT05113966 | Triple Negative... | Trilaciclib Sacituzumab Gov... | 18 Years - | G1 Therapeutics, Inc. | |
| A Multicenter Prospective Post-registration Study of Empegfilgrastim to Evaluate Safety and Efficacy in Special Cancer Populations | NCT04905329 | Solid Tumor High-Risk Cance... Breast Cancer Gastrointestina... Gynecological M... Myelosuppressio... | Empegfilgrastim | 18 Years - 80 Years | Moscow Clinical Scientific Center | |
| Application of MRI in Identifying Myelosuppression Risk of Neoadjuvant Chemoradiotherapy for Rectal Cancer | NCT04970498 | Rectal Cancer S... Rectal Cancer S... | MRI blood routine t... | - | Peking University Third Hospital | |
| Clinical Observation of Integrated Chinese Medicine With Western Medicine for the Reduction of Chemotherapy-induced Hematologic Toxicity | NCT05442177 | Myelosuppressio... | Chemotherapy an... | 18 Years - 80 Years | Taichung Tzu Chi Hospital | |
| PG2 Phase I/II Clinical Study Intravenously Administered in Patients With Advanced Malignancy | NCT01696565 | Neoplasm Metast... Neoplasm Recurr... | PG2 | 20 Years - 75 Years | PhytoHealth Corporation | |
| A Dose Finding Study of CycloSam® Combined With External Beam Radiotherapy | NCT03612466 | Osteosarcoma Bone Metastases | 153Sm-DOTMP External beam r... Calcium Carbona... Mozobil Neupogen Inject... | 15 Years - 65 Years | Albert Einstein College of Medicine | |
| Study of Trilaciclib and Lurbinectidin | NCT05578326 | Lung Cancer Small-cell Lung... | Trilaciclib Lurbinectedin | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Application of MRI in Identifying Myelosuppression Risk of Neoadjuvant Chemoradiotherapy for Rectal Cancer | NCT04970498 | Rectal Cancer S... Rectal Cancer S... | MRI blood routine t... | - | Peking University Third Hospital | |
| Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL) | NCT03098589 | Lymphoma | Revlimid | 18 Years - | Celgene | |
| Lifemel Honey to Reduce Leucopenia During Chemotherapy | NCT00243165 | Breast Cancer | Lifemel honey i... | 18 Years - | Rambam Health Care Campus | |
| A Multicenter Prospective Post-registration Study of Empegfilgrastim to Evaluate Safety and Efficacy in Special Cancer Populations | NCT04905329 | Solid Tumor High-Risk Cance... Breast Cancer Gastrointestina... Gynecological M... Myelosuppressio... | Empegfilgrastim | 18 Years - 80 Years | Moscow Clinical Scientific Center | |
| Efficacy and Safety Phase IIa Study of Myelo001 in Chemotherapy-Induced Neutropenia | NCT02692742 | Chemotherapy-In... Myelosuppressio... Breast Cancer | Myelo001 Placebo | 18 Years - | Myelo Therapeutics GmbH | |
| A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC | NCT05780294 | Nasopharyngeal ... Leucogen Chemotherapy Myelosuppressio... | 5-fu Lobaplatin Placebo leucogen | 18 Years - 60 Years | Sun Yat-sen University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
